Today, Epizyme Inc. (EPZM) Receives “Outperform” Rating from Wedbush

Today, Epizyme Inc. (EPZM) Receives “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of Epizyme Inc. (NASDAQ:EPZM) in a report published on Monday morning. Wedbush currently has a $22.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on EPZM. HC Wainwright reaffirmed a buy rating on shares of Epizyme in a research report on Tuesday, August 9th. Zacks Investment Research raised Epizyme from a sell rating to a hold rating in a research report on Wednesday, August 10th. Leerink Swann reaffirmed an outperform rating on shares of Epizyme in a research report on Friday, October 7th. Finally, JMP Securities reaffirmed a buy rating on shares of Epizyme in a research report on Sunday, November 6th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $23.11.

Epizyme (NASDAQ:EPZM) opened at 11.30 on Monday. Epizyme has a one year low of $7.02 and a one year high of $18.29. The stock’s 50 day moving average price is $9.94 and its 200 day moving average price is $9.79. The company’s market capitalization is $655.52 million.

Epizyme (NASDAQ:EPZM) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.18. The firm had revenue of $6.60 million for the quarter. Epizyme had a negative return on equity of 41.56% and a negative net margin of 1,205.01%. Equities analysts anticipate that Epizyme will post ($1.98) EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. BlackRock Group LTD boosted its stake in shares of Epizyme by 3.7% in the third quarter. BlackRock Group LTD now owns 10,374 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 371 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Epizyme during the second quarter worth $104,000. State Board of Administration of Florida Retirement System boosted its stake in shares of Epizyme by 15.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,347 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,102 shares during the period. BlackRock Advisors LLC boosted its stake in shares of Epizyme by 12.5% in the third quarter. BlackRock Advisors LLC now owns 21,244 shares of the biopharmaceutical company’s stock worth $209,000 after buying an additional 2,365 shares during the period. Finally, American International Group Inc. boosted its stake in shares of Epizyme by 36.2% in the second quarter. American International Group Inc. now owns 23,167 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 6,155 shares during the period. Hedge funds and other institutional investors own 79.69% of the company’s stock.

Epizyme Company Profile

Related posts

Leave a Comment